The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

Northeastern University scientists have discovered that a protein in the human brain could potentially be used to grow new ...